Boston Common Asset Management LLC Sells 79,101 Shares of Hologic, Inc. (NASDAQ:HOLX)

Boston Common Asset Management LLC decreased its position in Hologic, Inc. (NASDAQ:HOLX) by 25.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 227,564 shares of the medical equipment provider’s stock after selling 79,101 shares during the period. Boston Common Asset Management LLC owned approximately 0.10% of Hologic worth $16,405,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Federated Hermes Inc. bought a new stake in shares of Hologic during the second quarter valued at approximately $246,000. Envestnet Asset Management Inc. raised its position in Hologic by 3.6% in the second quarter. Envestnet Asset Management Inc. now owns 361,271 shares of the medical equipment provider’s stock worth $26,824,000 after acquiring an additional 12,671 shares during the period. Dimensional Fund Advisors LP grew its holdings in Hologic by 5.7% during the second quarter. Dimensional Fund Advisors LP now owns 2,326,992 shares of the medical equipment provider’s stock valued at $172,780,000 after purchasing an additional 124,739 shares during the period. Edgestream Partners L.P. bought a new position in shares of Hologic during the 2nd quarter valued at approximately $1,696,000. Finally, Mercer Global Advisors Inc. ADV lifted its holdings in Hologic by 31.1% during the second quarter. Mercer Global Advisors Inc. ADV now owns 72,220 shares of the medical equipment provider’s stock valued at $5,362,000 after purchasing an additional 17,130 shares in the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.75% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on HOLX shares. JPMorgan Chase & Co. raised their price target on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Wolfe Research initiated coverage on Hologic in a report on Friday, December 13th. They issued a “peer perform” rating on the stock. Royal Bank of Canada lifted their price objective on shares of Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 5th. Mizuho dropped their target price on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Tuesday, November 5th. Finally, Jefferies Financial Group started coverage on shares of Hologic in a report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 price target on the stock. Seven equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $88.92.

Hologic Trading Up 0.2 %

Shares of NASDAQ HOLX traded up $0.15 during trading hours on Friday, hitting $70.12. 217,537 shares of the company traded hands, compared to its average volume of 2,239,191. The company’s 50 day moving average price is $75.02 and its 200 day moving average price is $78.37. Hologic, Inc. has a 12 month low of $68.61 and a 12 month high of $84.67. The stock has a market capitalization of $15.91 billion, a price-to-earnings ratio of 21.07, a price-to-earnings-growth ratio of 2.44 and a beta of 0.97. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.01. The business had revenue of $987.90 million for the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business’s revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.89 earnings per share. On average, equities research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.